Ultramicronized palmitoylethanolamide restores astrocyte-neuron metabolic coupling and Klotho/FGF21 signaling in a triple-transgenic mouse model of Alzheimer's disease
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Triple-transgenic (3xTg-AD) mice, 6 and 12 months old
- Dose used in the study
- Not stated in the abstract
- Duration
- Chronic treatment, assessed at 6 and 12 months of age
- What was measured
- Brain lactate, glutamate/glutamine and taurine levels by MRI/MRS; FGF21, Klotho and insulin receptor expression; ADAM10/ADAM17 metalloprotease levels, by Western blot, in frontal cortex and hippocampus.
What the authors reported
3xTg-AD mice showed lactate build-up, glutamine/glutamate imbalance, taurine depletion and reduced FGF21, Klotho and insulin receptor expression. Um-PEA treatment rebalanced lactate-glutamate metabolism, increased taurine synthesis and transport, raised FGF21, Klotho and insulin receptor expression, and changed ADAM10 and ADAM17 metalloprotease levels.
Limits of this study
A transgenic mouse model study; it cannot show effect in people with Alzheimer's disease. Caterina Scuderi reports equipment, drugs or supplies provided by Epitech Group SpA, which makes ultramicronised PEA.
Source
PubMed 41496364 · doi:10.1016/j.biopha.2025.118965
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.